SIGA Reports Financial Results for Three Months Ended March 31, 2021

 Approximately $3 Million in International Sales of Oral TPOXX® in the First Quarter –

– Approximately $7 Million in International Sales of Oral TPOXX® in April –

Corporate Update Conference Call Today at 4:30 PM ET –

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2021.

“SIGA’s first quarter financial results reflect a positive general trend with international sales,” said Phil Gomez, CEO of SIGA. “In 2020, we had $2 million total of international sales, while in this first quarter alone, we’ve delivered approximately $3 million of oral TPOXX® to the Public Health Agency of Canada (“PHAC”), and in April we delivered an additional $7 million of oral TPOXX® to PHAC.  With respect to deliveries of oral TPOXX® to the Biomedical Advanced Research and Development Authority (“BARDA”), we continue to expect those sales pursuant to our 2018 Contract to be concentrated in the second half of 2021, in contrast to international sales which we expect to be concentrated in the first half of 2021.”

Summary Financial Results
($ in millions, except per share amounts)

Three Months Ended March 31, 2021 in comparison to Three Months Ended March 31, 2020

Three Months
March 31,
Three Months
March 31,
Total Revenues
Operating Loss (1)
Loss before Income Taxes (1)
Net Loss
Diluted Loss per Share

(1) Operating Loss excludes, and Loss before Income Taxes includes, costs in connection with the retirement of the Company’s term loan, interest expense, interest income and adjustments to the fair value of the Company’s outstanding warrant. Both line items exclude the impact of income taxes. 

Recent Key Activities:

  • In April and March 2021, the Company delivered approximately $7 million and $3 million, respectively, of oral TPOXX® to PHAC under the contract that was awarded in January 2021 (“2021 PHAC Contract”).  The April delivery will be reflected in the second quarter financial results.  The 2021 PHAC Contract, as well as the contract for the procurement of oral TPOXX® with the Canadian Military, were coordinated between SIGA and Meridian Medical Technologies, Inc. under the international promotion agreement (as amended) that was entered into by the parties in June 2019.
  • In April 2021, the Company filed a new drug application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for the intravenous formulation of TPOXX (“IV TPOXX®”).  The approval of a second formulation of TPOXX® would increase the addressable patient population to those who are too ill to swallow oral capsules. The FDA review process will typically take 10 months for this type of submission.
  • In March 2021, the Company announced a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to novel antibacterial drugs. The purpose of the strategic partnership is to provide BARDA, a department within the U.S. Department of Health and Human Services (“HHS”), with potential solutions for biothreat and public health needs in connection with anti-microbial resistance.

Share Repurchase Activity

During the first quarter of 2021, SIGA repurchased approximately 1 million shares of its common stock, for approximately $6.5 million.  Since the inception of the current share repurchase program in March 2020, the Company has cumulatively repurchased approximately 5.6 million shares of its common stock for approximately $35 million. 

COVID-19 Pandemic

The COVID-19 pandemic has caused significant societal and economic disruption.  Such disruption, and the associated risks and costs, are expected to continue for an indeterminate period of time.  Given the uncertain scale, scope, and current and future impact of the pandemic, the Company is regularly reviewing business and financial risks, and seeking coordination with its government partners with respect to the performance of current and future contract timing and execution.  Additionally, the Company is coordinating closely with service providers and vendors, in particular contract manufacturing organizations that constitute our supply chain, with respect to actions and risks caused by the COVID-19 pandemic. Finally, the Company has proactively provided its employees with resources and other support to help ensure continued success in remote work settings as they navigate the current pandemic environment.

The COVID-19 pandemic has not adversely affected the liquidity position of the Company, nor is it currently expected to have a material adverse effect on the financial condition of the Company.  The pandemic could delay the timing of international contract awards for oral TPOXX® given the need of government officials to focus on meeting the demands of the current COVID-19 pandemic. Otherwise, the pandemic is not currently expected to have a material adverse effect on the short-term financial results of the Company, although the Company cannot provide assurances as to the ultimate impact of the pandemic upon the broader macro environment or the Company’s industry.

Conference Call and Webcast

SIGA will host a conference call and webcast to provide a business update today, Thursday, May 6, 2021, at 4:30 P.M. ET.

Participants may access the call by dialing 1-800-891-3448 for domestic callers or 1-416-641-6700 for international callers. A live webcast of the call will also be available on the Company’s website at under the ‘Events & Presentations’ tab in the Investor Relations section, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 21993669. The archived webcast will be available in the Events and Presentations section of the Company’s website.


SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX® is a novel small-molecule drug and the US maintains a stockpile of 1.7 million courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX® was approved by the FDA for the treatment of smallpox in 2018. The full label is here:  In September 2018, SIGA signed a contract potentially worth more than $600 million with BARDA for additional procurement and development related to both oral and intravenous formulations of TPOXX®. For more information about SIGA, please visit

About Smallpox1

Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine’s side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.


This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA’s filings with the Securities and Exchange Commission, including SIGA’s Annual Report on Form 10-K for the year ended December 31, 2020, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC’s web site at Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

Investor Contacts:
Laine Yonker, Edison Group

Michael Crawford, Edison Group  


As of

    March 31, 2021     December 31, 2020  
Current assets                
Cash and cash equivalents   $ 106,527,495     $ 117,890,240  
Accounts receivable     4,001,259       3,340,263  
Inventory     20,410,371       20,265,519  
Prepaid expenses and other current assets     1,950,149       2,112,069  
Total current assets     132,889,274       143,608,091  
Property, plant and equipment, net     1,986,888       2,103,990  
Deferred tax assets, net     2,572,594       2,544,053  
Goodwill     898,334       898,334  
Other assets     419,448       676,923  
Total assets   $ 138,766,538     $ 149,831,391  
Current liabilities                
Accounts payable   $ 446,795     $ 1,278,217  
Accrued expenses and other current liabilities     7,064,722       9,205,293  
Total current liabilities     7,511,517       10,483,510  
Warrant liability     5,720,410       6,639,211  
Other liabilities     2,849,744       2,915,401  
Total liabilities     16,081,671       20,038,122  
Commitments and contingencies                
Stockholders’ equity                
Common stock ($.0001 par value, 600,000,000 shares authorized, 76,240,439 and 77,195,704, issued and outstanding at March 31, 2021 and December 31, 2020, respectively)     7,625       7,720  
Additional paid-in capital     225,211,481       224,978,430  
Accumulated deficit     (102,534,239 )     (95,192,881 )
Total stockholders’ equity     122,684,867       129,793,269  
Total liabilities and stockholders’ equity   $ 138,766,538     $ 149,831,391  


    Three Months Ended March 31,  
    2021     2020  
Product sales and supportive services   $ 3,523,343     $ 113,009  
Research and development     1,290,401       2,506,756  
Total revenues     4,813,744       2,619,765  
Operating expenses                
Cost of sales and supportive services     250,848       109,094  
Selling, general and administrative     4,056,184       3,176,024  
Research and development     2,302,785       3,150,105  
Patent expenses     193,334       182,597  
Total operating expenses     6,803,151       6,617,820  
Operating loss     (1,989,407 )     (3,998,055 )
Gain/(loss) from change in fair value of warrant liability     918,801       (16,065 )
Loss on extinguishment of Term Loan           (4,981,461 )
Interest expense           (3,016,817 )
Other income, net     25,568       412,363  
Loss before income taxes     (1,045,038 )     (11,600,035 )
Benefit for income taxes     232,933       2,702,506  
Net and comprehensive loss   $ (812,105 )   $ (8,897,529 )
Basic loss per share   $ (0.01 )   $ (0.11 )
Diluted loss per share   $ (0.02 )   $ (0.11 )
Weighted average shares outstanding: basic     76,757,010       81,240,105  
Weighted average shares outstanding: diluted     77,572,587       81,240,105  

error: Content is protected !!